专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20190282692A1 SELECTIVE LOCAL INHIBITION OF TNFR1-MEDIATED FUNCTIONS AT THE SITE OF ANTIGEN/ALLERGEN PRESENTATION 审中-公开
公开(公告)号：US20190282692A1
公开(公告)日：2019-09-19
申请号：US15921945
申请日：2018-03-15
申请人： Reinhard Bredehorst , Thomas Grunwald , Markus Ollert , Carsten Schmidt-Weber , Edzard Spillner
发明人： Reinhard Bredehorst , Thomas Grunwald , Markus Ollert , Carsten Schmidt-Weber , Edzard Spillner
IPC分类号： A61K39/39 , A61K39/35 , A61K38/20 , C12N15/113 , A61K9/127 , A61K47/34 , A61K39/00 , A61K9/06 , A61K39/395 , A61K31/713
摘要： The invention relates to a pharmaceutical composition for the modulation of T cell and B cell responses made of one or more preparations and comprising a therapeutically effective dose of at least one inhibitor of TNFR1-mediated functions and of at least one antigen or allergen.

2. 发明申请

US20220273791A1 SELECTIVE LOCAL INHIBITION OF TNFR1-MEDIATED FUNCTIONS AT THE SITE OF ANTIGEN/ALLERGEN PRESENTATION 有权
公开(公告)号：US20220273791A1
公开(公告)日：2022-09-01
申请号：US17491853
申请日：2021-10-01
申请人： Reinhard Bredehorst , Thomas Grunwald , Markus Ollert , Carsten Schmidt-Weber , Edzard Spillner
发明人： Reinhard Bredehorst , Thomas Grunwald , Markus Ollert , Carsten Schmidt-Weber , Edzard Spillner
IPC分类号： A61K39/39 , A61K39/395 , A61K31/713 , A61K38/20 , A61K39/35 , C12N15/113 , A61K9/06 , A61K9/127 , A61K39/00 , A61K47/34
摘要： The invention relates to a pharmaceutical composition for the modulation of T cell and B cell responses made of one or more prepatations and comprising a therapeutically effective dose of at least one inhibitor of TNFR1-mediated functions and of at least one antigen or allergen.

3. 发明授权

US07696323B2 Bivalent IgY antibody constructs for diagnostic and therapeutic applications 失效
标题翻译：用于诊断和治疗应用的二价IgY抗体构建体
公开(公告)号：US07696323B2
公开(公告)日：2010-04-13
申请号：US11510329
申请日：2006-08-25
申请人： Reinhard Bredehorst , Kerstin Greunke , Thomas Grunwald , Edzard Spillner
发明人： Reinhard Bredehorst , Kerstin Greunke , Thomas Grunwald , Edzard Spillner
IPC分类号： C07K16/00 , A61K39/395
CPC分类号： C07K16/40 , C07K16/10 , C07K16/462 , C07K2317/23 , C07K2317/41 , C07K2317/622 , C07K2317/64
摘要： This invention relates to the field of recombinant antibody technology. It provides novel recombinant IgY antibody constructs for diagnostic and therapeutical applications. The bivalent antibody constructs display a heterotetrameric or homodimeric format stabilized by disulfide bonds. The constant heavy chain domains CH2-CH4 are partly or completely of avian origin, whereas the VH, VL, CL, and CH1 domains as well as the hinge region may be of avian origin or derived from any other species. The invention allows to combine the advantages of IgY antibodies with those of established mammalian monoclonal antibodies. IgY antibody constructs comprising nonglycosylated IgY constant heavy chain domains allow to reduce unwanted interactions with C-type lectins, e.g., in human sera. Furthermore, chimeric IgY antibody containing mammalian VH, VL, CL, and CH1 domains as well as a mammalian hinge region provide a higher molecular stability than IgY antibodies in acidic conditions and, thereby, are especially suited for peroral therapeutic applications.
摘要翻译：本发明涉及重组抗体技术领域。它提供用于诊断和治疗应用的新型重组IgY抗体构建体。二价抗体构建物显示通过二硫键稳定的异四聚体或同二聚体形式。恒定的重链结构域CH2-CH4部分或完全是鸟类来源的，而VH，VL，CL和CH1结构域以及铰链区可以是鸟类来源的或衍生自任何其它物种。本发明允许将IgY抗体的优点与已建立的哺乳动物单克隆抗体的优点相结合。包含非糖基化IgY恒定重链结构域的IgY抗体构建体允许减少与C型凝集素的不期望的相互作用，例如在人血清中。此外，含有哺乳动物VH，VL，CL和CH1结构域以及哺乳动物铰链区的嵌合IgY抗体在酸性条件下提供比IgY抗体更高的分子稳定性，因此特别适用于口服治疗应用。

4. 发明申请

US20070141049A1 Bivalent IgY antibody constructs for diagnostic and therapeutic applications 失效
标题翻译：用于诊断和治疗应用的二价IgY抗体构建体
公开(公告)号：US20070141049A1
公开(公告)日：2007-06-21
申请号：US11510329
申请日：2006-08-25
申请人： Reinhard Bredehorst , Kerstin Greunke , Thomas Grunwald , Edzard Spillner
发明人： Reinhard Bredehorst , Kerstin Greunke , Thomas Grunwald , Edzard Spillner
IPC分类号： A61K39/395 , C07K16/44
CPC分类号： C07K16/40 , C07K16/10 , C07K16/462 , C07K2317/23 , C07K2317/41 , C07K2317/622 , C07K2317/64
摘要： This invention relates to the field of recombinant antibody technology. It provides novel recombinant IgY antibody constructs for diagnostic and therapeutical applications. The bivalent antibody constructs display a heterotetrameric or homodimeric format stabilized by disulfide bonds. The constant heavy chain domains CH2-CH4 are partly or completely of avian origin, whereas the VH, VL, CL, and CH1 domains as well as the hinge region may be of avian origin or derived from any other species. The invention allows to combine the advantages of IgY antibodies with those of established mammalian monoclonal antibodies. IgY antibody constructs comprising nonglycosylated IgY constant heavy chain domains allow to reduce unwanted interactions with C-type lectins, e.g., in human sera. Furthermore, chimeric IgY antibody containing mammalian VH, VL, CL, and CH1 domains as well as a mammalian hinge region provide a higher molecular stability than IgY antibodies in acidic conditions and, thereby, are especially suited for peroral therapeutic applications.
摘要翻译：本发明涉及重组抗体技术领域。它提供用于诊断和治疗应用的新型重组IgY抗体构建体。二价抗体构建物显示通过二硫键稳定的异四聚体或同二聚体形式。恒定的重链结构域C H-2-C H 4部分或完全是鸟类来源的，而V H H， L，C L和C H 1结构域以及铰链区域可以是鸟类来源的或衍生自任何其它物种。本发明允许将IgY抗体的优点与已建立的哺乳动物单克隆抗体的优点相结合。包含非糖基化IgY恒定重链结构域的IgY抗体构建体允许减少与C型凝集素的不期望的相互作用，例如在人血清中。此外，含有哺乳动物V H，V L，C L和C H H 1结构域的嵌合IgY抗体为以及哺乳动物铰链区域在酸性条件下提供比IgY抗体更高的分子稳定性，因此特别适合于口服治疗应用。

5. 发明申请

US20100081801A1 Method for determining an unknown PNA sequence and uses thereof 审中-公开
标题翻译：用于确定未知PNA序列的方法及其用途
公开(公告)号：US20100081801A1
公开(公告)日：2010-04-01
申请号：US11582165
申请日：2006-10-17
申请人： Reinhard Bredehorst , Jorn Glokler , Thomas Grunwald , Mark Matzas , Edzard Spillner
发明人： Reinhard Bredehorst , Jorn Glokler , Thomas Grunwald , Mark Matzas , Edzard Spillner
IPC分类号： C12Q1/68 , C40B30/04 , C07H21/04
CPC分类号： C12Q1/6874 , C07K2/00 , C12Q1/6869 , C12Q2525/107
摘要： The invention relates to a method for determining an unknown PNA sequence information of PNA molecules of a specific PNA molecule species, wherein, the PNA molecules are contacted with one or several different nucleic acid molecule species comprising nucleic acid molecules with at least one nucleotide, wherein the nucleic acid molecules at least partially comprise a nucleic acid sequence that is complementary to at least a partial sequence of the PNA molecule, wherein nucleic acid molecules having complementary sequences bind to the PNA molecules forming nucleic acid/PNA hybrids, wherein nucleic acid molecules with non-complementary sequences are separated from the nucleic acid/PNA hybrids, wherein thereafter the nucleic acid/PNA hybrids are dissociated into single stranded hybrid nucleic acid molecules and PNA molecules, wherein the single stranded hybrid nucleic acid molecules are subjected to a sequencing process providing hybrid sequence information about the single stranded hybrid nucleic acid sequence, and wherein the hybrid sequence information is optionally translated into the complementary PNA sequence information, and to a method for producing PNA molecules using such a process.
摘要翻译：本发明涉及一种用于确定特异性PNA分子物种的PNA分子的未知PNA序列信息的方法，其中所述PNA分子与包含具有至少一个核苷酸的核酸分子的一种或几种不同的核酸分子物质接触，其中所述核酸分子至少部分地包含与所述PNA分子的至少部分序列互补的核酸序列，其中具有互补序列的核酸分子与形成核酸/ PNA杂交体的PNA分子结合，其中核酸分子与非互补序列与核酸/ PNA杂交体分离，此后，核酸/ PNA杂交体解离成单链杂交核酸分子和PNA分子，其中单链杂交核酸分子经受测序过程，提供关于单链杂交体的杂交序列信息核酸序列，并且其中杂交序列信息任选地翻译成互补的PNA序列信息，以及使用这种方法产生PNA分子的方法。

6. 发明授权

US07553931B2 Complement depletion using recombinant human C3-derivatives 失效
标题翻译：使用重组人C3衍生物补体耗尽
公开(公告)号：US07553931B2
公开(公告)日：2009-06-30
申请号：US10884813
申请日：2004-07-02
申请人： Johanna Kölln , Edzard Spillner , Reinhard Bredehorst
发明人： Johanna Kölln , Edzard Spillner , Reinhard Bredehorst
IPC分类号： C07K1/00
CPC分类号： C07K14/472 , A61K38/00 , C07K2319/00
摘要： The invention provides isolated polypeptides having complement-modulating activity. Specifically, the invention resides in the provision of isolated polypeptides having complement-depleting properties, i.e. that effect an efficient consumption of complement in human serum. The current invention thus provides human C3-derivatives that are capable of forming C3-convertases exerting an extended CVF, Bb-like half-life of up several hours, compared to 1.5 minutes of the naturally occurring C3-convertases, thus escaping the physiological degradation mechanisms.
摘要翻译：本发明提供了具有补体调节活性的分离的多肽。具体地说，本发明在于提供具有补体消耗特性的分离的多肽，即在人血清中有效消耗补体。因此，本发明提供人类C3-衍生物，其能够与1.5分钟的天然存在的C3-转化酶相比，形成产生延长的CVF，类似Bb样的半衰期的C3-转化酶，从而逃避生理降解机制

7. 发明申请

US20050079585A1 Complement depletion using recombinant human C3-derivatives 失效
标题翻译：使用重组人C3衍生物补体耗尽
公开(公告)号：US20050079585A1
公开(公告)日：2005-04-14
申请号：US10884813
申请日：2004-07-02
申请人： Johanna Kolln , Edzard Spillner , Reinhard Bredehorst
发明人： Johanna Kolln , Edzard Spillner , Reinhard Bredehorst
IPC分类号： A61K38/00 , C07H21/04 , C07K14/47 , C12N9/64 , C12N15/12 , C12P21/04 , C12Q1/68
CPC分类号： C07K14/472 , A61K38/00 , C07K2319/00
摘要： The invention provides isolated polypeptides having complement-modulating activity. Specifically, the invention resides in the provision of isolated polypeptides having complement-depleting properties, i.e. that effect an efficient consumption of complement in human serum. The current invention thus provides human C-3 derivatives that are capable of forming C3convertases exerting an extended CVF,Bb-like half-life of up several hours, compared to 1.5 minutes of the naturally occurring C3convertases, thus escaping the physiological degradation mechanisms.
摘要翻译：本发明提供了具有补体调节活性的分离的多肽。具体地说，本发明在于提供具有补体消耗特性的分离的多肽，即在人血清中有效消耗补体。因此，本发明提供了人类C-3衍生物，其能够形成与1.5分钟的天然存在的转化酶相比，产生延长的CVF，类似Bb的半衰期的C3转化酶，从而逃避生理降解机制。

8. 发明授权

US08119769B2 Complement depletion using recombinant human C-3 derivatives 有权
标题翻译：使用重组人C-3衍生物补体耗尽
公开(公告)号：US08119769B2
公开(公告)日：2012-02-21
申请号：US12428889
申请日：2009-04-23
申请人： Johanna Kölln , Edzard Spillner , Reinhard Bredehorst
发明人： Johanna Kölln , Edzard Spillner , Reinhard Bredehorst
IPC分类号： C07K1/00
CPC分类号： C07K14/472 , A61K38/00 , C07K2319/00
摘要： The invention provides isolated polypeptides having complement-modulating activity. Specifically, the invention resides in the provision of isolated polypeptides having complement depleting properties, i.e. that effect an efficient consumption of complement in human serum. The current invention thus provides human C3 derivatives that are capable of forming C3 convertases exerting an extended CVF, Bb-like half-life of up several hours, compared to 1.5 minutes of the naturally occurring C3 convertases, thus escaping the physiological degradation mechanisms.
摘要翻译：本发明提供了具有补体调节活性的分离的多肽。具体而言，本发明在于提供具有补体耗尽特性的分离的多肽，即在人血清中有效消耗补体。因此，本发明提供能够形成C3转化酶的人类C3衍生物，其与自然存在的C3转化酶的1.5分钟相比，产生延长的CVF，类似Bb的半衰期几个小时，从而逃避生理降解机制。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式